Scheduled to close around January 19, 2024, the offering's net proceeds are earmarked for scaling operations to accommodate Medicare Part B patients, following CMS's establishment of coverage and proposed pricing for Myomo's MyoPro product line. This outlook hinges on receiving a final fee from the Centers for Medicare and Medicaid Services  CMS  that is not significantly lower than the preliminary fee, successful staff expansion, and avoiding unusual supply chain disruptions.
Myomo plans to close its offering around January 19, 2024, with net proceeds earmarked for scaling operations to accommodate Medicare Part B patients, contingent on receiving a final fee from CMS that is not significantly lower than the preliminary fee, successful staff expansion, and avoiding unusual supply chain disruptions.